Budgets can be high with animal experiments. This has to do with how time and labor intensive the studies are, resources needed for animal care, long-term nature of the studies (if applicable), material and equipment costs, and compliance with regulations. Considering this, it is not worth shortening the time frame with the consequence of increasing risk. A failed study can harm the development process, with there being a need to pinpoint the source of failure, address this source of failure, and then re-do the animal experiment itself. Given the high budget of the experiment, this can prove incredibly harmful to the future outlook of the project. Of course, this is in consideration of there being no mitigation of risk in response to the shortened timeline. From my co-op experience, I have learned that studying of cells and tissues via in vitro methods prior to an animal study to solidify expected data can help mitigate risks related to animal experiments. Considering this, if faced with the need to shorten the time frame and accept the risk of failure in the animal experimental study, what methods would you use to mitigate risk? Would you do so via addressing aspects of the animal study itself (such as procedure or animal used), or would there be a more external solution?

I agree with the points raised about the long-term consequences of rushing through experimentation, especially when it comes to medical devices where safety and effectiveness are importanst. Cutting corners in the short term can easily backfire if the data isn't strong enough to support regulatory approval or if key design flaws go unnoticed. That said, I think it’s also important to acknowledge that in real-world scenarios, time and budget constraints are very real pressures. It seems like the best approach might be to focus on streamlining planning and communication early in the project so that experiments are well-designed from the start and delays can be minimized without sacrificing quality. It’s definitely a tough balance to strike but I think that thoughtful risk assessment can go a long way in deciding when a time tradeoff is acceptable.

The mini-sim was luckily set in a way where civilized conversations solved the problems. We were lucky that the people involved trusted each other's opinions and experience. It is not always like this in the world. Sometimes management does not care about the reasonings of delays, just that they do not exist, even it it costs quality. A different path that I could have chosen was shortening the animal testing timeline. That really made me feel uncomfortable as I was scared how it would affect the FDA assessment and we would not know the longevity of the product. Sometimes a risk can be worth it, especially small risks with small results, but I tend to like staying on the safe side.

Time delays for a project especially in the medical device field is an incredibly harrowing situation to be placed in because of prior expectations. Sometimes certain delays can already be factored into the project, while others are completely unprecedented and can lead to major setback brought on by confusion over the product. I believe that a project team's method of navigating through these delays are an accurate method to showcase how well the product's are going to fare with the public. A project not having delays or being completed in a relatively quick schedule does not immediately ensure it's quality. In my opinion it is always worth it to lengthen the time frame of a project if it ensures that the quality of the product enhances or even lowers the amount of risk. This can be a hard sell to do for project mangers of course, so it is almost always the case where a middle ground must be met for the project completion to reach a date that is more acceptable for the stakeholders to manage. Though it should not go understated how important it is to fully flesh out a project especially in the medical device industry because of how big of an impact it can have across the world. 

A lot of points listed here I agree with, especially with increasing project risk just to shorten the schedule could be a dangerous path, especially in medical device development. In the miniSim example, reducing the animal study timeline significantly from 16 weeks to 4 might save time initially, but it increases the chance that long term biological responses or complications could be missed in these crucial steps. If the problems appear later during verification, validation or regulatory review, the project could face even worse delays later on. While there may be situations where small risks are accept to keep a project along and going, those decisions could only be made after some careful assessment to risk. In a lot of cases, especially in this sector, it could be better to allow more time for testing to ensure reliable data and safety to patients.

In the minisim, shortening the animal experiment timeline increases risk because it can lead to incomplete or unreliable data. While it may seem like time is being saved upfront, it could actually create bigger delays later if the study needs to be repeated. There can also be a chance that by cutting the animal studies short, an issue may not be detected. For something like animal testing, the quality of the data is critical, so rushing the process can negatively impact the entire validation. 

I think reducing the timeline is only worth it to a certain extent. If the changes do not significantly affect the accuracy or reliability of the results, then it is okay. However, for key validation steps, it is important to be cautious and make sure any added risk is understand and controlled. Otherwise, the project could face even greater setbacks down the line. 

At what point does saving time become more harmful than helpful in a situation like this?

In many projects, time problems happen and need to be handled to keep things moving. Usually, good communication helps solve these issues, but sometimes it is not enough. In that case, the team may need to make changes to the plan or accept some level of risk. In the mini-simulation, reducing the time for animal studies helped save time but increased the project risk. This shows there is a trade-off between finishing faster and having reliable results. If time is reduced too much, important data might be missed. So, it is important to think carefully before making this decision. I think shortening the timeline is only okay if the risks are understood and controlled.

While it may be beneficial to take a risk to shorten the projects time frame, this decision depends heavily on the magnitude of the benefit, and the size and impact of the risk being incurred. In the example displayed by the minisim, of drastically reducing the length of the animal trials to reduce the project time by several weeks is a completely unreasonable risk to take. The consequences of such a risk would involve potentially redoing all of the animal trials from scratch, which could potentially kill the whole project. While doing the full animal trial would put the project behind the initial schedule, it didn't seem that the project was in danger of being cancelled due to this delay. Just based on the risk/reward ratio it did not seem like a reasonable chance to take. Deciding whether to incur additional risk to your project to shorten the time frame is a decision that will be different every time based on the risk to reward. 

Teams may need to make decision-making decisions that take into account some level of risk rather than complete agreement when team members cannot reach an agreement on key elements of a project due to time limitations and lack of discussion. In Medical Device Projects in particular, decisions regarding timing should never be made quickly as they have significant implications for both product performance and safety. While I do believe shortening the timeline may sometimes be appropriate, I also firmly believe that such action would need to include a clear understanding of the associated risks and proper mitigation strategies through additional testing or added developmental safeguards. Therefore, I truly believe there is a need to find a middle ground relative to time vs. risk. Is there ever a good enough reason to place a priority on speed or should safety always be placed at the top of the list?

As many people have pointed out in this thread already, rushing the animal experimentation opens up the project to extra risk later down the road. Animal testing takes a significant amount of time. I've done a lot of work in that field, and that's what anyone who works with animal testing would tell you. Animal testing is unpredictable and can present lengthy delays. Ideally, when the project timeline is first created, whoever is directing the animal testing would advise adding in some sort of buffer time for any of these unexpected delays. As covered in the minisim briefly, to do animal testing, you need to order animals, give them some time to acclimate, do any pre-dosing examinations, dose the animals or perform surgery on them (depending on the test you want to do), provide aftercare, investigate at the pre-determined timepoints for your protocol, and potentially sacrifice the animals at the end before doing explants and histlogical analysis. This is assuming that everything goes smoothly on the first try. Yes, delays can be costly and hard to explain, but it is worth not rushing the animal testing results. Animal testing is a stage before clinical testing, and when dealing with medical devices, peoples' lives are on the line. In my opinion, the only scenario where a shortening of timeline would be acceptable is if it's a very minute change that cuts into the buffer time, not the experimental endpoints time.